Original Article

The Level of Antithrombin III (AT III) in Turkish Diabetics

Volume 2 · Issue 4 Publish Date: March 18, 2022
Full Text PDF
Füsun Hamulu
Ege University, Department of Endocrinology, Izmir, Turkey
Şevki Çetinkalp
Ege University Medical School, Division of Endocrinology and Metabolism, Izmir, Turkey
Ahmet Gökhan Özgen
Ege University Medical School, Division of Endocrinology and Metabolism, Izmir, Turkey
Fırat Bayraktar
Ege University, Department of Endocrinology, Izmir, Turkey
Candeğer Yılmaz
Ege Üniversitesi Tıp Fakültesi, Endokrinoloji ve Metabolizma Bilim Dalı, İzmir, Turkey
Taylan Kabalak
Ege University Medical School Department of Endocrinology and Metabolic Diseases, Izmir, Turkey
Mehmet Tüzün
Ege Üniversitesi Tıp Fakültesi, Endokrinoloji ve Metabolizma Bilim Dalı, İzmir, Turkey
Hamulu, F., Çetinkalp, Şevki, Özgen, A. G., Bayraktar, F., Yılmaz, C., Kabalak, T., & Tüzün, M. (2022). The Level of Antithrombin III (AT III) in Turkish Diabetics. Endocrinology Research and Practice, 2(4), 209–212. Retrieved from https://endocrinolrespract.org/index.php/pub/article/view/65
Full Text Full Text PDF

Abstract

ABSTRACT
A natural anti-coagulant AT III plays a defensive role against intravascular coagulation and regulates blood hemostasis. Diabetes is associated with hypercoagulable state. The level of blood AT III levels in the Turkish diabetic population have been studied. 100 diabetic patients (2 type 1, 75 type 2) and 20 healthy control were included in the study. AT III levels were 34.75 mg/dl in healthy control, and 41.89 mg/dl in the diabetic group (p<0.0001). There was no difference between type 1 and type 2 diabetics (p=0.16). This study showed that serum AT III levels increased in both type 1 and type 2 diabetics. The level of AT III did not have any correlation with duration of diabetes, blood glucose, HbA1c, lipid levels and diabetic complications (p>0.05). Treatment type (diet, oral anti-diabetics and insulin) did not affect AT III levels (p>0.05).
Article Info
Published In
Journal Endocrinology Research and Practice
Volume / Issue Volume 2 · Issue 4
Pages 209-212
History
Published Online March 18, 2022
Copyright
Affiliations
Füsun Hamulu
Ege University, Department of Endocrinology, Izmir, Turkey
Şevki Çetinkalp
Ege University Medical School, Division of Endocrinology and Metabolism, Izmir, Turkey
Ahmet Gökhan Özgen
Ege University Medical School, Division of Endocrinology and Metabolism, Izmir, Turkey
Fırat Bayraktar
Ege University, Department of Endocrinology, Izmir, Turkey
Candeğer Yılmaz
Ege Üniversitesi Tıp Fakültesi, Endokrinoloji ve Metabolizma Bilim Dalı, İzmir, Turkey
Taylan Kabalak
Ege University Medical School Department of Endocrinology and Metabolic Diseases, Izmir, Turkey
Mehmet Tüzün
Ege Üniversitesi Tıp Fakültesi, Endokrinoloji ve Metabolizma Bilim Dalı, İzmir, Turkey
Cite this Article
Hamulu, F., Çetinkalp, Şevki, Özgen, A. G., Bayraktar, F., Yılmaz, C., Kabalak, T., & Tüzün, M. (2022). The Level of Antithrombin III (AT III) in Turkish Diabetics. Endocrinology Research and Practice, 2(4), 209–212. Retrieved from https://endocrinolrespract.org/index.php/pub/article/view/65
Outlines